Urine Tumor DNA for Bladder Cancer Monitoring
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 56 (estimated)
- Sponsor
- Lahey Clinic · Other
This trial is looking for patients with non-muscle invasive bladder cancer. Participants will help determine if testing urine for tumor DNA can allow for less frequent check-ups with cystoscopy.
You may be able to join if
- I have high-risk bladder cancer
- I have received BCG or gemcitabine/docetaxel treatment
- I had a negative result after my initial therapy assessment
You may not be able to join if
- I have high-risk NMIBC within the last 3 years
- I have had prior induction intravesical therapy
- I have variant histology
- I have concurrent upper tract disease
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Loading trial locations…